Prof Heather Payne

Dr Heather PayneTel: 020 3447 9105

University College Hospital

Radiotherapy, Urological Cancers, Prostate Cancer

Professional background

Professor Payne was appointed as a Consultant in Clinical Oncology at University College Hospital, London in 1997. She trained at St Marys Hospital London  Medical School and after qualifying spent some working in general medicine both in London and also in Haiti. She returned to London to train as a clinical oncologist and during this time developed an interest in urological oncology. She has a busy practice specialising in the management of urological malignancies in London where she works within a multidisciplinary team. She is actively involved in clinical research in all these therapeutic areas and has pioneered a programme of high dose-rate brachytherapy for prostate cancer at the UCH site.

Professor Payne's current research interests also include hormone therapy as adjuvant treatment for locally advanced disease, sensitisation of hormones and radiotherapy, maximal androgen blockade, predictive indices for bowel toxicity with radiotherapy, chemotherapy and quality of life and decision-making for men with prostate cancer. She is principal investigator in a number of international multi-centre and local studies. She is a trustee of the Prostate Cancer Research Centre and the chairman of the British Uro-oncology Group (BUG). She also serves on CTAAC, the Prostate Cancer Charter for Action, and the Department of Health Prostate Cancer Advisory Group for the United Kingdom.

Research interests

  • Urological tumours
  • prostate cancer (special interest)
  • Active surveillance
  • Radiotherapy
  • High dose-rate brachytherapy
  • Chemotherapy
  • Novel agents and clinical trials


Management of Locally Advanced Prostate Cancer
Heather Payne
Asian Journal of Andrology (2009) 11:1 pages 81-90

Patient-reported outcomes of a randomized placebo-controlled Phase II trial
of the specific endothelin A receptor antagonist ZD4054 in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer
Payne H et al. Eur Urol 2009; 8 page 133

Efficacy of leuprorelin 3.75mg compared to 7.5mg in the treatment of prostate cancer: systematic review and meta-analysis
Payne H, Edwards SJ
Value in Health, ISPOR 11: Volume 11, Issue 6,page 335, 2009

What you need to know about Prostate Cancer
Roger Kirby and Heather Payne
Pulse Issue 16th June 2009

Chemotherapy decision based on wellness and not chronological age
Heather Payne
Medicine Matters 2009 Issue 52 page 4

 Radiation in High Risk Prostate Cancer - How much is enough?
Heather Payne
BJUI Vol. 102, 2008 issue 6, page 663

Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.
Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T.
Prostate Cancer Prostatic Dis. 2008;11(1):46-52.

The effect of ZD4054 on bone metastases in patients with M1 hormone-resistant prostate cancer as assessed by radionuclide bone scans
Nick James,1 Nancy Dawson,2 Armelle Caty,3 Michael Borre,4 Bernard Zonnenberg,5 Philippe Beuzeboc,6 Teuvo Tammela,7 Jesper Andersen,8 Stephane Culine,9
Heather Payne,10 Thomas Morris11 and De Phung11

Optimizing decisions about treatment in locally advanced prostate cancer.
Payne H Lim F
Br J Hosp Med (Lond). 2007 May;68(5):252-6.

An Algorithm for the Management of External Beam Radiotherapy Failure in Prostate Cancer
Tim Dudderidge, Heather Payne, Mark Emberton
BJU Int. March 2007 Jun 15

Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK
Heather A Payne, David A Gillatt
BJUInt 2007– Mar 07, issue 3, pages 545-553

Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.
Parker C, Sydes MR, Kynaston H, Logue J, Murphy C, Morgan R, Mellon K, Maresh C, Parulekar W, Parmar MK, Payne H, Savage C, Stansfeld J
(The RADICALS Trial Management group)
BJU Int. 2007 Apr 8 p1376-1379

Transdermal Oestrogen Therapy as a Second-Line Hormonal Intervention in
Prostate Cancer: A Bad Experience.
Kandol S, Anyamene N,Payne HA, Harland SJ
BJU Int. 2007 Jan;99(1):53-5.

Combined androgen blockade is underused in advanced prostate cancer: findings from an international survey
Castro-Diaz D,1 Gillat D,2 Payne H,3 Akaza H4
Urologia Internationalis. 2007

Prostate Cancer- Ensuring Evidence Based Prescribing
Heather Payne, Mike Kirby, Dermot Ball, Lawrence Drudge-Coates, Jas Kambh, Geoff Saunders
Pulse, Ed April 2007

Urinary Toxicity after Treatment of High Risk Prostate Cancer using HDR Brachytherapy Boost.
Gayadeen SA, Armstrong E,Solano J, De Souza D, Sullivan T, Payne HA
Clinical Oncology 2007 Apr;19(3):S29

RADICALS (Radiotherapy and Androgen Deprivation In Combination After Local Surgery
Chris Parker1, Noel Clarke2, John Logue3, Heather Payne4, Charles Catton5, Howard Kynaston6, Claire Murphy7, Rachel Morgan7, Chris Morash8, Wendy Parulekar9, Max Parmar7, Colleen Savage9, Jim Stansfeld10 and Matthew Sydes Clinical Oncology Volume 19 No3 pp167-171

Bladder cancer – management and future directions
Christopher Evansa,*, Frans Debruyneb, Heather Paynec, Eduardo Solsonad, Pierre Teillace, Andrea Tubarof
European Urology Volume 6 Issue 3 March 2007 pp 365-373

Treatment options in prostate cancer once primary therapy fails
Thomas Keanea,*, David Gillattb, Colleen Lawtonc, Heather Payned, Bertrand Tombale
European Urology Volume 6 Issue 3 March 2007 pp 344-353

Localised and locally advanced prostate cancer: who to treat and how?
David Gillatta,*, Laurence Klotzb, Colleen Lawtonc, Kurt Millerd, Heather Paynee
European Urology Volume 6 Issue 3 March 2007 pp 334-343

GMC/GDC number: 2822301